Monitoring of Antiplatelet Therapy in Children on Ventricular Assist Device Support: Comparison of Multiplate and...

Area of Science:

• Pediatric Cardiology
• Hematology
• Biomedical Engineering

Background:

• Monitoring antiplatelet therapy is crucial for children with ventricular assist devices (VADs).
• The optimal method for assessing antiplatelet efficacy in this population remains unclear.
• Current methods may not accurately reflect platelet function in pediatric VAD patients.

Purpose of the Study:

• To compare the reliability of Thromboelastography Platelet Mapping (TEG/PM) and multiple electrode platelet aggregometry (MEA) for monitoring antiplatelet therapy in children with VADs.
• To evaluate antiplatelet dose-response relationships and intraindividual variability using both methods.
• To determine which assay is superior for guiding antiplatelet treatment in pediatric VAD support.

Main Methods:

• Retrospective analysis of 66 paired blood samples from 9 pediatric patients (<16 years) on VAD.
• Simultaneous measurement of platelet function using TEG/PM and MEA (Multiplate analyzer).
• Assessment of agreement, dose-response, and intraindividual variability for aspirin and clopidogrel.

Main Results:

• Poor agreement between TEG/PM and MEA in determining therapeutic antiplatelet response (arachidonic acid κ=0.23, ADP κ=0.13).
• Higher rates of aspirin and clopidogrel resistance detected by TEG/PM compared to MEA.
• Significant dose-response with clopidogrel and MEA (R²=0.56), but not with TEG/PM (p=0.15).
• Greater intraindividual variability in platelet reactivity measured by TEG/PM during steady-state therapy.

Conclusions:

• Multiple electrode platelet aggregometry (MEA) demonstrates greater reliability than TEG/PM for monitoring antiplatelet therapy in pediatric VAD patients.
• MEA provides more consistent and clinically relevant assessment of antiplatelet effects in this population.
• These findings suggest MEA should be preferred for optimizing antiplatelet management in children with VADs.